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mologists) were randomly assigned to either intervention
(I) or control (C  standard practice) groups, and were
expected to enroll 10 adult patients with persistent
asthma (ATS criteria).
RESULTS: Two physicians withdrew after randomiza-
tion (I:1, C:1) but before starting recruitment. A total of
200 patients ( I:100, C:100) were recruited and 173 com-
pleted the study (C:86, I:87). The ITT analysis showed a
greater reduction of SGRQ values in group I that was sig-
nificant at the 5% level or marginally non-significant (p 
0.06) depending on the method of analysis, but always
clinically significant. Resource consumption and some
clinical variables (such as the number of symptom-free
days and nights) favored group I (p  0.05). The recom-
mendations were adopted in about 63% of the cases but
this seemed to depend on disease severity.
CONCLUSIONS: The intervention improved QoL, clini-
cal outcomes and resource consumption. The Spanish
recommendations for the management of APs should be
revised for severe cases.
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OBJECTIVE: The aim of the study was to assess the cost-
effectiveness of almitrine in the treatment of severe,
chronic obstructive pulmonary disease.
METHODS: A retrospective approach was applied. Both
costs and consequences of the therapy in two groups of
patients, almitrine group and placebo group, were as-
sessed. The pharmacoeconomic analysis was based on the
results of a clinical trial entitled “Effects of sequential ad-
ministration of almitrine bismesylate (100mg per day per
os) in 120 patients with chronic obstructive pulmonary
disease. One year, double blind study versus placebo”.
The effectiveness of the therapies was exemplified by sig-
nificant changes in arterial oxygen partial pressure (D
PaO2). The differences on Visual Analogue Scale for dys-
pnoea were also measured. Results of the trial demon-
strated significant improvement in PaO2 during 12-
months of treatment with almitrine compared to placebo.
Direct medical costs of pharmacological treatment, hos-
pitalizations, additional examinations and oxygen ther-
apy were identified and calculated. The societal and
third-party-payer perspectives were applied.
RESULTS: The total cost per patient per year in the alm-
itrine group amounted to 2 656 PLN and was 27 PLN
lower than for the placebo group. The most important
difference in cost components concerned costs of hospi-
talizations and oxygen therapy, which were 47.4% and
34.5% lower in almitrine group (calculations made from
societal perspective). Results of simulation assuming pos-
sibility of partial, subtotal or total reimbursement deter-
mined that savings due to this procedure might vary from
93 PLN per patient per year in the case of total reim-
bursement to 531 PLN per patient per year in the case of
50% reimbursement.
CONCLUSION: Cost calculations together with clinical
results determined that treatment with almitrine is a cost-
effective alternative, which leads to clinical improvement
and constitutes effective use of resources both from the
broad societal perspective and also from the third-party-
payer perspective.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease
(COPD) causes great disability, primarily among the el-
derly. A Dutch cost-of-illness study estimated the yearly
cost of care for an average patient to be Fl 1800 in 1993.
The purpose of this paper is to compute the lifetime cost
of COPD and to evaluate the contribution of medication,
hospital, and other types of care to this cost.
METHODS: The average life expectancy of a new COPD
patient was computed with a dynamic lifetable model for
the Netherlands. The model accounts for competing
death risks from other smoking-related diseases. Re-
source use and costs for three age groups and nine types
of care came from large representative registries. Sensitiv-
ity analyses were performed a/o., for the cost of a day in
hospital and for medication costs.
RESULTS: Male COPD patients diagnosed at age 45 and
65 have a life expectancy that is almost six and more
than two years less than the average life expectancy at
these ages. Expected lifetime costs for COPD are between
DFL 460 000 and 570 000 for men and women diag-
nosed at age 45. New patients at age 65 have lower costs:
between DFL 81 000 and 110 000 for men and DFL 102
000 and 152 000 for women. A large decrease in life ex-
pectancy that differs for men and women explains the re-
duction. Lower boundaries use minimum estimates for
the price of a hospital day and upper boundaries use high
estimates. Hospital and medication costs together con-
tribute to more than 80% of total lifetime cost. The con-
tribution of medication costs to the expected lifetime cost
decreases with age at diagnosis from 45% to 30%.
CONCLUSION: The lifetime cost reflects the importance
of hospital costs and medication costs to the total cost of
COPD. It is known that the number of COPD patients
will increase in the near future. The results of this work
may help understand the increasing health-care needs of
these patients.
